Shares of Perrigo PRGO rose 0.6% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share fell 12.26% over the past year to $0.93, which missed the estimate of $1.00.
Revenue of $1,290,000,000 declined by 2.49% from the same period last year, which missed the estimate of $1,320,000,000.
Guidance
Perrigo sees FY21 adjusted EPS of $2.50-$2.70.
Details Of The Call
Date: Mar 01, 2021
Time: 08:00 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1059/40062
Price Action
52-week high: $62.25
Company's 52-week low was at $38.20
Price action over last quarter: down 10.73%
Company Profile
Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.